Filing Overview
This Form 8-K was filed by Vallon Pharmaceuticals, Inc. on February 24, 2023, under Item 2.02 to announce financial results for the year ended December 31, 2022, and provide a business update. The filing identifies the registrant as Vallon Pharmaceuticals, Inc., not GRI Bio, Inc.; the provided text does not explain this discrepancy.
Financial Results and Liquidity
The filing states that a related press release contains the 2022 financial results and business update, but the press release text and financial figures are not included in the provided filing content. Accordingly, revenue, net income or loss, cash flow, margins, debt, cash, liquidity, and other financial metrics are not clearly available.
Material Changes and Outlook
The provided text does not describe material changes versus the prior comparable period, management guidance, operating outlook, risks, contingencies, or unusual items. These matters may have been addressed in Exhibit 99.1, which is referenced but not reproduced.
Filing Mechanics
- The information was furnished under Item 2.02 and was not deemed filed for purposes of Section 18 of the Exchange Act.
- The information was not deemed incorporated by reference into other SEC filings.
- Exhibit 99.1 is identified as a press release dated February 24, 2023.
- The company reported common stock trading under the symbol VLON on The Nasdaq Capital Market.
Key Facts to Verify
- Confirm the correct registrant, since the request metadata names GRI Bio, Inc., while the filing names Vallon Pharmaceuticals, Inc.
- Obtain and review Exhibit 99.1 for the actual 2022 financial results, cash position, cash burn, and liquidity outlook.
- Verify any reported year-over-year changes, guidance, business milestones, financing activities, and going-concern or funding-risk disclosures.